Successful listing of Shanghai Ecmoho Health Biotechnology Co., Ltd. one of CID Greater China Venture Capital Fund V
Nov 8, 2019
The CID Group (“CID”) is pleased to announce the successful listing of Shanghai Ecmoho Health Biotechnology Co., Ltd (“Ecmoho” or “the Company”), one of CID Greater China Venture Capital Fund V, L.P (“Fund”) portfolio companies, on the Nasdaq (Stock symbol: MOHO) on November 8th, 2019.
Established in 2011 and headquartered in Shanghai, Ecmoho is a leading non-medical health and wellness integrated solution provider in China. With its experiences in health industry and retail management, Ecmoho has the strengths to offer comprehensive value proposition to stakeholders in the health & wellness ecosystem. The Company provides value-added services such as global marketing, cross-border warehousing supply chain, and established online and offline distribution channels to brand partners. On the other hand, it delivers consumers globally well-known quality brands and products with integrated solutions customizing their needs such as Gerber and Abbott in maternal care, J&J and Unilever in personal and household health care, and GNC and Centrum in nutritious supplements. The financial growth is also substantial, the revenues reached US$151 million in the first half of 2019, YoY growth 112%.
CID Fund V invested US$5.8 million in Ecmoho. In addition to Ecmoho’s outstanding management team, CID has supported the Company since the investment in 2015 on strategic development, networks and resources connection, talent recruitments, as well as our financing expertise and IPO planning. Based on the latest closing price, the market cap of Ecmoho is USD 333 million, achieving 2.7x multiple.
For the last two decades, CID has been focusing on venture investments and industry integration opportunities in the Greater China market. CID has invested in 194 companies and achieved 119 exits.
Ample Electronic Technology Co., Ltd. Listed on Taipei Exchange (Fund III)
Apr 3, 2019
The CID Group (“CID”) is delighted to announce that Ample Electronic Technology Co., Ltd. (“Ample”, Stock Code 4760:TT), one of CID Greater China Venture Capital Fund III, L.P (“Fund III”) portfolio companies, has successfully transferred to the Main Board from the Emerging Board of Taipei Exchange on March 21st, 2019.
Founded in 2007, Ample is specializing in producing conductive silver paste, silver palladium paste, copper and nickel paste, etc, in applicable to a variety of industries including photovoltaic (PV), touch panels, flexible circuitry, solar energy, as well as passive components. Its dedication in innovation, product testing equipment, and process equipment simulation increase products yield rates and strengthen Ample's gross margin. As of end of 2018, Ample booked NTD 713M revenue and 56M net profit with 60% YoY growth.
CID Fund III invested Ample in 2010, and has been working closely with the company in exploring products application other than passive components to different industries. We also utilized resources to build strategic alliance for the company’s growth, and facilitated the IPO preparation. Based on the closing price of the latest trading day, the market cap of Ample is NTD 916 million, achieving 2.2x multiple for CID’s investment.
For the last two decades, CID has been focused on venture investments and industry integration opportunities in the Greater China market. CID has invested in 194 companies and achieved 117 exits.
Transn (China) Technology Co.,Ltd. Trade Sale (Fund II)
Apr 3, 2019
We are also pleased to announce the successful trade sale of Transn (China) Technology Co.,Ltd (“Transn”, Stock Code: 835737.NE), a portfolio company of CID Greater China Fund II (“Fund II”), on March 29th, 2019.
After Transn listed on China’s National Equities Exchange and Quotations (NEEQ), a.k.a. “New Third Board” on February 29th, 2016, the company has accelerated its endeavor to become a global leader of cloud-based multilingual translation platform. Today, with over 800 employees and over 30,000 freelance translators worldwide, Transn has become biggest translation platform in China and no. 3 in Asia. As of 1H2018, Transn reported RMB 141M revenue and 15M net profit.
Fund II invested USD 5.5 million in Transn. As an early investor partner, CID has contributed in the company’s development, such as management team establishment, business strategies tuning, alliance seeking and negotiation, as well as financing support. Based on the negotiated sale price, the Fund has generated 2.6x multiple cash returns with this exit.